SRNE : Summary for Sorrento Therapeutics, Inc. - Yahoo Finance

U.S. Markets open in 4 hrs 36 mins

Sorrento Therapeutics, Inc. (SRNE)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.80+0.10 (+5.88%)
At close: 4:00PM EDT
People also watch
NKLBIOTGTXRGLSBLCM
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close1.70
Open1.75
Bid1.50 x 20000
Ask5.00 x 2400
Day's Range1.70 - 1.85
52 Week Range1.55 - 8.35
Volume1,277,953
Avg. Volume504,825
Market Cap91.6M
Beta1.88
PE Ratio (TTM)-1.49
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube4 days ago

    ETFs with exposure to Sorrento Therapeutics, Inc. : April 20, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Sorrento Therapeutics, Inc. Here are 5 ETFs with the largest exposure to SRNE-US. Comparing the performance and risk of Sorrento Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • PR Newswire5 days ago

    Sorrento Announces Closing of Public Offering of Common Stock

    The securities described above were offered by Sorrento pursuant to a shelf registration statement on Form S-3 (File No. 333-199849) previously filed with and declared effective by the Securities and Exchange Commission (the "SEC") on December 3, 2014.  A final prospectus supplement and accompanying prospectus related to the offering was filed with the SEC on April 14, 2017 and is available on the SEC's website at http://www.sec.gov.  Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by telephone at 212-829-7122, or by e-mail at prospectus@cantor.com. Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for immuno-oncology, inflammation and autoimmune diseases.

  • 24/7 Wall St.11 days ago

    Sorrento Therapeutics Gears Up for Secondary Offering

    Sorrento Therapeutics saw its shares plunge on Thursday after the company announced a secondary offering.